4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $13.00 by Analysts at SVB Securities

4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) had its target price lowered by SVB Securities from $14.00 to $13.00 in a report released on Thursday morning, The Fly reports. Several other equities analysts also recently weighed in on FDMT. SVB Leerink reduced their price target on 4D Molecular Therapeutics from $15.00 to $14.00 and set […]

Related Keywords

David Kirn ,Scott Bizily ,D Molecular Therapeutics Inc ,Barclays Plc ,Securities Exchange Commission ,Lazard Asset Management ,Denali Advisors ,Belpointe Asset Management ,Ensign Peak Advisors Inc ,Molecular Therapeutics ,Get Rating ,Moderate Buy ,Molecular Therapeutics Stock Down ,Exchange Commission ,Asset Management ,Peak Advisors Inc ,Molecular Therapeutics Daily ,4d Molecular Therapeutics ,Nasdaq Fdmt ,Fdmt ,Medical ,Lower Price Target ,Svb Securities ,